連網型糖尿病照護：創新與成長機會

連續血糖監測、人工胰臟系統和新型胰島素配方改變了糖尿病管理的未來

人們越來越偏好使用穿戴式 CGM 來進行糖尿病自我評估，以取代指尖血糖值測量，尤其是第 1 型糖尿病 (T1D) 患者。目前，HbA1c 和 TIR 是糖尿病監測應用的首選生物標記。新的飲食/健身追蹤應用程式可以支持您的整體健康，並幫助預防與文明病，例如糖尿病。先進人工智慧 (AI) 的使用透過提供對生理標記的預測見解（包括預測血糖值）來實現這些應用程式的預測能力。 2 型糖尿病 (T2D) 的傳統處方藥包括口服藥物。儘管如此，胰島素用於 T2D 治療的使用仍在增加，特別是對於口服藥物無法控制血糖值的患者。由於胰島素輸送平台的不斷進步，胰島素仍然是 T1D 患者的主要治療方法。

混合封閉回路型系統或人工胰腺正在迅速成為 T1D 最佳管理的首選治療選擇。這些系統通常由複雜的演算法組成，促進 CGM、胰島素幫浦以及監測和輸送平台之間的串擾，以持續管理血糖值。擴大使用連接到智慧型手機應用程式的穿戴式監測設備，可以實現基於應用程式的個人化建議和可操作的預測見解，以改善糖尿病管理，推動數位療法的發展。這項研究提供了連續血糖監測、胰島素輸送技術和人工胰臟進展的見解。我們也分析了將塑造全球糖尿病照護未來的資金籌措、新興數位糖尿病照護技術以及合作關係。

目錄

改變糖尿病照護產業

• 為什麼成長如此困難？
• The Strategic Imperative 8（TM）
• 關鍵策略要務對連網型糖尿病護理產業的影響
• 成長機會推動Growth Pipeline Engine（TM）
• 調查方法

成長機會分析

• 糖尿病盛行率和相關健康風險概述
• 數位化糖尿病照護簡介
• 分析範圍
• 分割

成長發電機

• 生長促進因子
• 成長抑制因素

血糖監測技術

• 穿戴式 CGM 概述
• CGM 景觀簡介
• CGM 及相關應用程式分析
• 新 CGM 創新
• 要點與展望

HCL胰島素輸送系統

• HCL 胰島素輸送系統概述
• 人工胰臟情況簡介
• 人工胰臟系統及相關應用分析
• HCL 領域的新創新
• 要點與展望

胰島素輸送技術

• 胰島素輸送技術概述
• 胰島素輸送競爭格局概況
• 最近/即將到來的胰島素輸送創新
• 主要觀點及展望

資金籌措、合作夥伴關係和收購

• 資金籌措分析
• 主要合作夥伴和收購
• 糖尿病照護 - 觀點

成長機會宇宙

• 成長機會 1：非侵入性連網型血糖感測器
• 成長機會2：小型穿戴式人工胰腺
• 成長機會3：口服胰島素

下一步

Continuous Glucose Monitoring, Artificial Pancreas Systems, and Novel Insulin Delivery Formulations to Transform the Future of Diabetes Management

The preference for diabetes self-assessment using wearable CGMs instead of finger-stick blood sugar testing is increasing, especially in type 1 diabetics (T1D). HbA1c and time-in-range are currently the preferred biomarkers for diabetes monitoring applications. Emerging diet and fitness tracking apps help support general well-being and prevent the onset of lifestyle diseases such as diabetes. The use of advanced artificial intelligence (AI) has enabled the predictive capabilities of these apps by providing predictive insights on physiological markers, including the prediction of blood glucose levels. Conventional prescription medications for type 2 diabetes (T2D) comprise oral drugs. Still, there is a rising use of insulin for T2D management, especially for patients who are unable to manage blood sugar levels with oral medicines. Insulin continues to be a mainstay for treating T1D patients, with continuous advances in insulin delivery platforms.

Hybrid closed-loop systems or artificial pancreas are fast emerging as a preferred treatment option for optimally managing T1D. These systems typically comprise a CGM, an insulin pump, and an advanced algorithm that facilitates cross talk between the monitoring and delivery platforms for managing blood sugar levels continuously. The rising use of wearable monitoring devices connected through smartphone apps has enabled several app-based personalized recommendations and actionable predictive insights for improved diabetes management, leading to digital therapeutics development. This research provides insights into advancements in CGMs, insulin delivery technologies, and artificial pancreas. The study also analyzes funding, emerging digital diabetes care technologies, and partnerships shaping the future of global diabetes care.

The study answers the following questions: What are the key technological advancements in CGM devices and insulin delivery platforms? Who are the key innovators across device-based diabetes care platforms? How are funding and partnership trends likely to impact the diabetes care device industry? What are the emerging trends for digital diabetes care? What are the growth opportunities for digital diabetes management?

Table of Contents

Transformation in the Diabetes Care Sector

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Connected Diabetes Care Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Overview of Diabetes Prevalence and Associated Health Risks
• Snapshot of Digital Diabetes Care
• Scope of Analysis
• Segmentation

Growth Generator

• Growth Drivers
• Growth Restraints

Glucose Monitoring Technologies

• Overview of Wearable CGMs
• Snapshot of the CGM Landscape
• Analysis of CGMs and Related Apps
• Emerging CGM Innovations
• Key Takeaways and Outlook

HCL Insulin Delivery Systems

• Overview of HCL Insulin Delivery Systems
• Snapshot of the Artificial Pancreas Landscape
• Analysis of Artificial Pancreas Systems and Related Apps
• Emerging Innovations Across the HCL Landscape
• Key Takeaways and Outlook

Insulin Delivery Technologies

• Overview of Insulin Delivery Technologies
• Snapshot of the Competitive Landscape for Insulin Delivery
• Recent and Upcoming Insulin Delivery Innovations
• Key Takeaways and Outlook

Funding, Partnerships & Acquisitions

• Funding Analysis
• Key Partnerships and Acquisitions
• Diabetes Care-Outlook

Growth Opportunity Universe

• Growth Opportunity 1: Noninvasive Connected Glucose Sensors
• Growth Opportunity 2: Miniaturized Wearable Artificial Pancreas
• Growth Opportunity 3: Oral Insulin

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Take the Next Step
• Legal Disclaimer